The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice

Essentials•Factor Xa (FXa)‐targeting direct oral anticoagulants (DOACs) reduce venous thromboembolism (VTE)•The effects of FXa‐targeting DOACs on cancer progression remain to be studied•In xenograft models, a FXa‐targeting DOAC did not inhibit breast cancer growth and metastasis•A thrombin‐targeting DOAC, dabigatran, also did not inhibit breast cancer growth and metastasisAbstract Background:Factor Xa‐targeting DOACs were recently found to...